IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3579
+0.0026 (0.73%)
Aug 14, 2025, 2:19 PM - Market open
IGC Pharma Employees
IGC Pharma had 70 employees as of March 31, 2025. The number of employees increased by 3 or 4.48% compared to the previous year.
Employees
70
Change (1Y)
3
Growth (1Y)
4.48%
Revenue / Employee
$18,157
Profits / Employee
-$101,729
Market Cap
30.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 70 | 3 | 4.48% |
| Mar 31, 2024 | 67 | 6 | 9.84% |
| Mar 31, 2023 | 61 | 9 | 17.31% |
| Mar 31, 2022 | 52 | 2 | 4.00% |
| Mar 31, 2021 | 50 | 0 | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IGC News
- 2 days ago - IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1 - Accesswire
- 9 days ago - IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression - Accesswire
- 22 days ago - IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025 - Accesswire
- 24 days ago - IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards - Accesswire
- 4 weeks ago - IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection - Accesswire
- 6 weeks ago - IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation - Accesswire
- 6 weeks ago - IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - Accesswire
- 7 weeks ago - IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon - Accesswire